IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent XXXX .

@entity1 @entity135 @entity137 @entity82 @entity548 @entity39 @entity2347 @entity957 @entity1503 @entity850 @entity902
PURPOSE: In this retrospective investigation, the outcome and @entity137 after reirradiation with concurrent cetuximab immunotherapy of recurrent @entity135 ( @entity135 ) in @entity1 who had contraindications to @entity902 -based chemotherapy were analyzed. MATERIALS AND METHODS: Ten @entity1 with locally advanced recurrent @entity135 were retrospectively evaluated. In 9 cases, histology was @entity957 , in one case @entity2347 . External beam radiotherapy was part of the initial treatment in all cases. Reirradiation was carried out using step-and-shoot intensity-modulated radiotherapy (IMRT) with a median dose of 50.4 Gy. Cetuximab was applied as loading dose (400 mg/m(2)) 1 week prior to reirradiation and then weekly concurrently with radiotherapy (250 mg/m(2)). RESULTS: The median overall survival time after initiation of reirradiation was 7 months; the 1-year overall survival (OS) rate was 40%. Local failure was found in 3 @entity1 , resulting in a 1-year local control (LC) rate of 61%. The 1-year locoregional control (LRC) rate was 44%, while the 1-year distant metastasis-free survival (DMFS) was 75%. Acute @entity1503 was not observed in the group. Severe acute @entity137 included one fatal infield @entity548 and one flap @entity39 . Severe late @entity137 were noted in 2 @entity1 : @entity82 of the temporomandibular joint in 1 @entity1 and @entity850 of the cervical esophagus in another. CONCLUSIONS: IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent @entity135 is feasible with acceptable acute @entity137 . Further investigations are necessary to determine the clinical role of this therapy concept.
